Phase II Asthma Trial

Study Basics

- Disease: Asthma
- Phase: Ⅱ
- Target Geography: US

Background

When planning their trial, a sponsor faced two key challenges: reaching engaged community sites and improving patient diversity. To overcome these challenges and achieve their enrollment goals, they partnered with Inato to connect with high-performing sites that could drive both reach and representation.

The Problem

The sponsor faced challenges with engaging sites and reaching a more diverse patient population. Asthma clinical trials often struggle with recruitment and representation, as traditional site selection tends to favor large academic centers that become over saturated and may not be easily accessible to underserved or rural communities. This centralization creates logistical barriers for patients and contributes to the underrepresentation of key populations. To overcome these hurdles and meet their enrollment goals, the sponsor partnered with Inato to connect with untapped, high-performing sites and enhance access to diverse patients.

98.7%

OF THE
PATIENTS
ENROLLED ON
INATO WERE
DIVERSE




SITES ACHIEVED

181%

OF INATO'S ENROLLMENT COMMITMENT

The Solution

To address the sponsor's challenges in expanding their site engagement and improving diversity, Inato provided a targeted, data-driven approach to site selection and activation. Inato identified and engaged 30 community-based sites with the capacity to enroll diverse patients. Inato's vetting process ensured that each recommended site had the experience, infrastructure, and patient reach necessary for successful participation in the trial. These sites were eager and ready to get started. Ultimately, 17 sites were selected, well beyond the 10 initially planned, demonstrating the sponsor's confidence in Inato's network. The sites leveraged Inato's new pre-screening tool, enabling them to engage with patients at scale and efficiently screen candidates. This technology streamlined the recruitment process by identifying eligible patients faster, reducing site burden, and accelerating overall enrollment timelines.



One of the key advantages of Inato's approach was its ability to connect the sponsor with sites already embedded in diverse communities. These sites had established relationships with underrepresented patient populations and a track record of successfully enrolling them in clinical research. By leveraging Inato's network, the sponsor exceeded their diversity target, enrolling 85% Hispanic patients compared to the original 16% goal.

Interested in finding the right sites for your trial?

Reach out today at contact@inato.com